PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172232
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172232
Extracellular Matrix Patches market size was valued at US$ 36,901.4 Million in 2025, expanding at a CAGR of 7.3% from 2026 to 2033.
Extracellular matrix (ECM) patches represent biological materials created from decellularized tissues and possessing a structure similar to the original one but without cells. These tissues consist of several molecules, such as collagen, glycosaminoglycans, growth factors, and so on, which make them capable of creating the perfect conditions for cell proliferation and tissue regeneration. Additionally, patches like these can be used as a surgical material when performing various procedures like wound healing, hernia repair, vascular surgery, and tissue reconstruction. In fact, the major feature of ECM materials is their biocompatibility and biodegradability, which contribute to the generation of new tissues. Thus, ECM patches are a good biocompatible and biodegradable platform for tissue regeneration during surgery.
Extracellular Matrix Patches Market- Market Dynamics
Rising Prevalence of Cardiovascular Diseases to propel market demand
The increasing prevalence of cardiovascular diseases is propelling the Extracellular Matrix Patches market growth. These patches help in the repair, regeneration, and restoration of cardiac tissues that are damaged. The use of these patches is common in cardiovascular procedures where heart defects and heart tissues are repaired. In July 2025, according to the World Health Organization (WHO), the number of deaths caused by cardiovascular diseases (CVDs) was about 19.8 million worldwide, which accounted for about 32% of all deaths.
The study also shows that 85% of CVD deaths are related to heart attacks and stroke. Furthermore, more than 75% of CVD deaths in the world happen in low and middle income countries. Finally, about 38% of the 18 million deaths that were caused by non-communicable diseases below the age of 70 years were due to CVDs. The growing prevalence of cardiovascular diseases is a significant factor driving the extracellular matrix patches market.
The Global Extracellular Matrix Patches market is segmented on the basis of Application, Raw Material, End User, and Region.
Under Application Outlook, Cardiac Repair holds a key role in the Extracellular Matrix Patches market because extracellular matrix patches help in tissue regeneration and repair of the damaged cardiac tissues. In May 2025, according to the National Heart Foundation of Australia Org., out of the total number of 49,000 patients surveyed, only 30% of patients got referred for cardiac rehabilitation; however, just 28% of these patients attended the program. It is clear that cardiac rehabilitation needs immediate attention, and the number of referred patients needs to increase since each and every patient in Australia undergoing a heart event needs to be referred to cardiac rehabilitation. As middle-incomeation, cardiac rehabilitation must be made compulsory for all those patients in Australia having undergone any heart event. Thus, with the increasing awareness and treatment methods, there are high chances of an increase in the adoption of cardiac rehabilitation.
Extracellular Matrix Patches Market- Geographical Insights
North America remains one of the most significant markets because of the increasing cases of heart diseases and defects, as well as injuries from various sports and trauma. For instance, in January 2026, according to the U.S. Centers for Disease Control and Prevention (Gov), about 7 out of every 10 ED visits resulting from TBI and concussion related to sports and recreational activities were reported among patients under 17 years old. Additionally, it is revealed that the male gender aged below 17 years old has almost double the number of ED visits for TBI and concussions related to sports and recreational activities as girls of the same age. For children below 17 years old, the contact sports such as football, basketball, and soccer accounted for 45% of ED visits for TBI and concussions. Such an alarming figure requires the use of preventive strategies to minimize sports injuries in the U.S.
Malaysia Extracellular Matrix Patches market - Country Insights
Malaysia boosts its position as a regional hub for medical device distributors and clinical education due to growing healthcare infrastructure and cooperation between the industry participants. In 2026, according to the Malaysian Investment Development Authority (Gov), more than 10 million health travellers visited Malaysia, generating a tourism income of approximately 30% of rehabilitation. High-throughput hospitals have experienced a 30% decrease in the incidence of complications, which encourages the development of specialized facilities as well as the use of advanced medical technologies. The result is the improvement of the healthcare environment of the country, which makes it a good place for offering special treatment and medical tourism. These increases in the adoption of Malaysia's healthcare capacity and its position as a regional destination for specialized treatment and medical tourism.
Some of the major participants operating in the Extracellular Matrix (ECM) Patches market include MTF Biologics, LeMaitre Vascular, Inc., Boston Scientific Corporation, Cook Medical, and Aroa Biosurgery. These companies manufacture bio-derived substances that support tissue repair and regeneration by using methods such as product development, collaborations, and market penetration to grow their market share and establish a competitive advantage. In December 2025, LeMaitre Vascular purchased the assets of AndraValvulotome products of Andramed GmbH, thus enabling the company to diversify its portfolio of vascular surgery products. The deal was valued at USD 1.8 million, which can further rise to USD 0.8 million on the basis of certain conditions. Hence, innovation and acquisitions are crucial for gaining a competitive advantage in the ECM patches market.
In January 2026, Boston Scientific Corporation announced that it had signed a definitive deal to acquire Penumbra, Inc. for approximately USD 14.5 billion to build on its portfolio of solutions in the cardiovascular business with mechanical thrombectomy and neurovascular intervention products.
In January 2026, Aroa Biosurgery announced that it had entered into a definitive exclusive US distribution agreement with Royal Biologics for its Myriad Matrix(TM) Restore to increase its penetration into ambulatory and mobile surgery through extracellular matrix-based soft tissue regeneration.